Curis, Inc. (CRIS)
After hours:
| Previous Close | 5.14 |
| Open | 5.06 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 5.00 - 5.23 |
| 52 Week Range | 3.80 - 17.49 |
| Volume | |
| Avg. Volume | 46,234 |
| Market Cap | 29.954M |
| Beta (5Y Monthly) | 3.32 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -8.17 |
| Earnings Date | Oct 31, 2024 - Nov 04, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.50 |
PR NewswireCuris Announces the 3rd Annual Symposium on IRAK4 in Cancer
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced the 3rd Annual Symposium on IRAK4 in Cancer taking place virtually on September 26, 9:00 AM-1:00 PM E.T.
- PR Newswire
Curis to Participate at the Upcoming 2024 Cantor Fitzgerald Global Healthcare Conference
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate in a fireside chat at the 2024 Cantor Fitzgerald Global Healthcare Conference later today at 4:15 PM ET. Details for the webcast can be found using the Cantor webcast link.
- PR Newswire
Curis to Present at Upcoming Healthcare Conferences in September
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences:
